LEAP2 and Alzheimer disease: In view of the contribution of glucose and lipid dysmetabolism to the development of AD (78), the increased LEAP2/ghrelin molar ratio in older adults might be a systemic change to accommodate metabolic changes during aging and, thus, prevent AD and other age-related conditions.